May 6, 2025 06:57 AM EDT
R&D

Aldeyra plots third FDA fil­ing for dry eye dis­ease drug af­ter lat­est Phase 3 da­ta

Ayisha Sharma

News Reporter

Aldeyra Ther­a­peu­tics isn’t giv­ing up on its drug can­di­date for dry eye dis­ease de­spite a chal­leng­ing path so far.

The com­pa­ny is prepar­ing to file …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

An­oth­er Bris­tol My­ers ex­ec goes to Aca­dia; David South­well takes CEO job at ARCH-backed can­cer biotech

Sanofi, Re­gen­eron re­port un­der­whelm­ing COPD da­ta for IL-33 an­ti­body, shares drop

As a chal­leng­ing first half nears a close, bio­phar­ma un­cer­tain­ty per­sists

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times